Madhu Kumar

Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneuropathy, or TTR-FAP, Chardan explained how the results support a pair...

Madhu Kumar of Chardan Capital Markets maintains a Sell rating on Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) ahead of the company's R&D Day on April 24. In a research report published Monday, Kumar highlighted his skepticism surrounding the company's Fast Track designation of Coversin, a...

At its R&D Day in New York City on December 16, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) discussed its clinical pipeline of RNAi drugs, including the phase III APOLLO trial of patisiran for transthyretin familial amyloid polyneuropathy (TTR-FAP). Chardan Capital’s Madhu Kumar...

Arbutus Biopharma Corp (NASDAQ: ABUS) reported additional data from the Phase II trial of ARB-1467, its RNAi drug for the treatment of chronic hepatitis B virus (HBV). Citing safety concerns related to ARB-1467, Chardan Capital Markets’ Madhu Kumar downgraded the rating on the company from...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced the discontinuation of all its clinical RNAi programs, citing safety issues. This development could boost Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s market share in both HBV (hepatitis B virus) RNAi and (alpha-1 antitrypsin), Chardan...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced it was discontinuing all its clinical RNAi programs. All these programs use the dynamic polyconjugate (DPC) platform in the EX-1 delivery vehicle. Chardan Capital’s Madhu Kumar downgraded the rating on the company to Neutral, while...

Clovis Oncology Inc’s (NASDAQ: CLVS) lead asset rucaparib has a poor risk-benefit profile. The candidate’s lack of efficacy over current treatments and safety signals represent “considerable risks” ahead of its PDUFA in February next year, Chardan Capital Markets’...

Chardan Capital’s Madhu Kumar believes Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is faced with several challenges, including lack of clinical data and presence of “competitive barriers” for targeted indications. Kumar initiated coverage of the company with a Sell rating...

Chardan has upgraded Arbutus Biopharma Corp (NASDAQ: ABUS) to Neutral following its underperformance versus Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and the S&P biotech index. Over the past month, Arbutus shares have dropped 26 percent, in contrast to both Arrowhead shares (+11 percent) and...

Chardan Capital Markets analysts Madhu Kumar and Gbola Amusa kept a Buy rating on Regulus Therapeutics Inc (NASDAQ: RGLS) following the positive top-line data on Hepatitis C virus treatment. The brokerage boosted its price target to $20 from $15.00 on the shares. The analysts said their...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) reported positive data in a Phase II study of its lead product ARC-520 for the treatment of hepatitis B surface antigen [HBsAg] in HB envelope antigen-positive [HBeAg+] HBV patients. Chardan Capital’s Madhu Kumar initiated coverage of the company...